Xofigo 1100 kBq/mL solution for injection

DRUG7 trials

Sponsors

UZ Leuven, Bayer Consumer Care AG, Bayer AG, European Organisation For Research And Treatment Of Cancer, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., Swiss Group for Clinical Cancer Research

Conditions

Castration resistant prostate cancer patients metastatic to bone.Metastatic castration-resistant prostate cancerOligoprogressive metastatic castration-refractory prostate cancerProstate cancermetastatic Castration-Resistant Prostate Cancer (mCRPC)metastatic castrate resistant prostate cancer (mCRPC)metastatic castration resistant prostate cancer (mCRPC)symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

Phase 1

DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.

Active, not recruitingCTIS2024-518985-29-02

Amsterdam UMC StichtingProstate cancer

Start: 2024-11-21Target: 6Updated: 2025-07-22

Phase 2

Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)

RecruitingCTIS2024-511660-89-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

Start: 2017-06-09Target: 70Updated: 2025-06-06

SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial

RecruitingCTIS2024-512132-29-00

Swiss Group for Clinical Cancer ResearchMetastatic castration-resistant prostate cancer

Start: 2025-08-06Target: 100Updated: 2025-05-22

Phase 3

Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial

RecruitingCTIS2022-502254-13-00

UZ LeuvenOligoprogressive metastatic castration-refractory prostate cancer

Start: 2023-12-18Target: 246Updated: 2025-07-18

EORTC 1333-GU: A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone (PEACE III)

Active, not recruitingCTIS2023-510453-41-00

European Organisation For Research And Treatment Of CancerCastration resistant prostate cancer patients metastatic to bone.

Start: 2015-10-26Target: 255Updated: 2024-08-23

DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Active, not recruitingCTIS2024-513867-19-00

Memorial Sloan Kettering Cancer Centermetastatic Castration-Resistant Prostate Cancer (mCRPC)

Start: 2019-01-31Target: 285Updated: 2025-12-04

Phase 4

(20510) A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH

Active, not recruitingCTIS2023-505830-89-00

Bayer Consumer Care AG, Bayer AGmetastatic castrate resistant prostate cancer (mCRPC)

Start: 2020-08-05Target: 514Updated: 2025-10-07